PA
Perceptive Advisors Portfolio holdings
AUM
$5.06B
1-Year Est. Return
314.02%
This Fund
S&P 500
1 Year Est. Return
+314.02%
AUM
$5.06B
AUM Growth
-$396M
(-7.3%)
Holding
136
Top Buys
| 1 | +$101M | |
| 2 | +$70.2M | |
| 3 | +$59.9M | |
| 4 |
Ionis Pharmaceuticals
IONS
|
+$39.8M |
| 5 |
BioCryst Pharmaceuticals
BCRX
|
+$33.2M |
Top Sells
| 1 | +$122M | |
| 2 | +$95.6M | |
| 3 | +$93.3M | |
| 4 |
FOLD
Amicus Therapeutics
FOLD
|
+$90.7M |
| 5 |
ATXS
Astria Therapeutics
ATXS
|
+$84.9M |
Sector Composition
| 1 | Healthcare | 99.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Praxis Precision Medicines
PRAX
$7.49B
| $656M | 12.96% |
2,035,986
+40,000
|
|
||
2
Celcuity
CELC
$4.38B
| $357M | 7.05% |
3,127,200
-33,000
|
|
||
3
Ascendis Pharma A/S
ASND
$13.3B
| $350M | 6.92% |
1,531,421
+450,000
|
|
||
4
Roivant Sciences
ROIV
$20.6B
| $230M | 4.53% |
8,285,461
+300,000
|
|
||
|
CNTA
5
Centessa Pharmaceuticals
CNTA
$6.16B
| $209M | 4.13% |
5,258,903
+2,341,269
|
|
||
6
Rhythm Pharmaceuticals
RYTM
$5.88B
| $206M | 4.08% |
2,373,795
-172,596
|
|
||
7
Spyre Therapeutics
SYRE
$6.33B
| $191M | 3.77% |
3,783,225
+714,000
|
|
||
8
Nuvalent
NUVL
$7.26B
| $162M | 3.2% |
1,580,505
-84,600
|
|
||
9
Edgewise Therapeutics
EWTX
$3.94B
| $139M | 2.75% |
4,423,974
-34,000
|
|
||
10
Protagonist Therapeutics
PTGX
$6.07B
| $130M | 2.56% |
1,230,879
-119,546
|
|
||
11
Apogee Therapeutics
APGE
$6.31B
| $130M | 2.56% |
1,540,384
-790,267
|
|
||
12
Travere Therapeutics
TVTX
$4.14B
| $123M | 2.43% |
4,142,551
-135,629
|
|
||
13
Amylyx Pharmaceuticals
AMLX
$1.49B
| $115M | 2.27% |
8,284,882
|
|
||
14
Immatics
IMTX
$1.34B
| $102M | 2.02% |
10,383,456
|
|
||
15
Relay Therapeutics
RLAY
$3.35B
| $97M | 1.92% |
9,751,141
+7,847,896
|
|
||
16
Inhibrx
INBX
$1.35B
| $97M | 1.92% |
1,442,707
-10,000
|
|
||
17
MeiraGTx Holdings
MGTX
$854M
| $89.3M | 1.76% |
10,326,103
|
|
||
18
Zymeworks
ZYME
$1.79B
| $87.9M | 1.74% |
3,510,078
+248,228
|
|
||
19
Solid Biosciences
SLDB
$667M
| $85.7M | 1.69% |
11,906,646
+73,107
|
|
||
20
Dyne Therapeutics
DYN
$2.9B
| $84.6M | 1.67% |
4,668,839
+1,189,895
|
|
||
|
21
BioCryst Pharmaceuticals
BCRX
$2.11B
| $70.8M | 1.4% |
7,434,033
+4,271,504
|
|
||
|
ORKA
22
Oruka Therapeutics
ORKA
$3.34B
| $68.4M | 1.35% |
1,395,501
-81,000
|
|
||
23
Artivion
AORT
$990M
| $60M | 1.18% |
1,637,290
-85,000
|
|
||
24
Nurix Therapeutics
NRIX
$1.67B
| $57.5M | 1.14% |
3,710,877
+155,000
|
|
||
25
Nautilus Biotechnolgy
NAUT
$344M
| $48.9M | 0.97% |
12,594,211
|
|